Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023

Rhea-AI Summary

Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced it will release its fourth quarter and fiscal year 2022 financial results after market close on March 1, 2023. Management will hold a conference call at 5:00 p.m. ET on the same day to discuss the financial results and provide a corporate update, followed by a Q&A session. Investors can access the live webcast through the company’s website or via teleconference links provided in the announcement. Organogenesis specializes in regenerative medicine, particularly for advanced wound care and surgical markets, offering innovative product solutions to meet patient needs.

Positive

• Announcement of forthcoming financial results provides transparency to investors.
• Scheduled conference call allows investors to engage with management and gain insights.

Negative

• None.

CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2022 financial results will be reported after the market closes on Wednesday, March 1st.

Management will host a conference call at 5:00 p.m. Eastern Time on March 1st to discuss the results of the quarter and fiscal year, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

 

FAQ

When will Organogenesis report its fourth quarter and fiscal year 2022 results?

Organogenesis will report its fourth quarter and fiscal year 2022 results after market close on March 1, 2023.

What time is the Organogenesis conference call scheduled?

The conference call is scheduled for 5:00 p.m. Eastern Time on March 1, 2023.

How can I access the Organogenesis conference call?

You can access the live webcast and teleconference through links provided in the press release or on the company’s website.

What does Organogenesis specialize in?

Organogenesis specializes in regenerative medicine, focusing on advanced wound care and surgical and sports medicine markets.